

# SYNTHESIS OF SOME NEW THIAZOLYL CHROMENONE DERIVATIVES BY USING $\alpha,\alpha$ - DIBROMOKETONES

<sup>1</sup>Pooja, <sup>2</sup>Monika Chahar\*, <sup>3</sup>Parul, <sup>4</sup>Vijay Kiran\*, <sup>5</sup>Jasbir Sangwan

<sup>1-3</sup>Department of Chemistry, B.M.U., Asthal Bohar, Rohtak, Haryana, India

<sup>4</sup>Department of Chemistry, C.R.A. College Sonipat, Haryana, India

<sup>5</sup>Department of Chemistry, Tau Devi Lal Govt. College for Women, Murthal, Sonipat, India

**Email ID:** <sup>2</sup>monikachahar2009@gmail.com, <sup>4</sup>poonivijaykiran@gmail.com

Accepted: 07.01.2023

Published: 01.02.2023

**Keywords:** Heterocyclic compounds, Thiazoles, Thiosemicarbazide, Cyclization,  $\alpha,\alpha$ -Dibromoketones.

## Abstract

*In organic synthesis, Thiosemicarbazide becomes one of the finest approach for the preparation of various heterocyclic compounds. Those reactions which contains C=O and C=N categories with thiosemicarbazide results in the composition of bioactive compounds specifically thiazoles. Hydrazine fragment contains a internal nitrogen centre which is the most softer nucleophilic centre as compared to effective absolute nitrogen, promoters allowing to nucleophilic replacement by the powerful nitrogen experienced cyclisation reaction to provide excellent yield of heterocycles under mild conditions. In the current study, some new derivatives of coumarin turned out to be formulated by treating “3-acetyl-2H-chromen-2-one” with hydrazinecarbothioamide subsequently cyclize with ethyl acetoacetate and then proceed with  $\alpha,\alpha$ - dibromoketones with the help of Hantzsch thiazole synthesis and to prepare other compounds and their pharmaceutical importance. All the compounds were identified by spectral details and physical evidence.*

## Paper Identification




\*Corresponding Author

© IJRTS Takshila Foundation, Monika Chahar & Vijay Kiran, All Rights Reserved.


## INTRODUCTION

Utilization of  $\alpha,\alpha$  Dibromoketones as systematized precursor for the preparation of heterocyclic compounds acquiring greater recognition due to their reliability and specificity throughout reactions.<sup>1-13</sup> In this investigation,  $\alpha,\alpha$ - Dibromoketones are operated for the establishment of thiazole nucleus implementing altered hantzsch thiazole synthesis (HTS)<sup>14-19</sup>. In the company of distinct synthetic procedures obtainable for the thiazoles. HTS is appreciably notable familiar appeal whichever comprises open chain reactants,  $\alpha$ - functionalized carbonyl compounds (C-C) and thioamides to raise the nucleus. In modified HTS the utility of  $\alpha,\alpha$  Dibromoketones is considerable because in case of  $\alpha$ - bromoketones due to low melting, lachrymosity and toxicity it is very difficult to handle. Thiazoles are one of the most prominent class of heterocyclic compounds which are existing in various natural products like thiamine pyrophosphate (TPP), carboxylase vitamin B1, penicillin and thiostrepton etc. In medicinal and pharmaceutical world, coumarins and thiazoles modified drugs have extensive effects on living matter such as antifungal, antiangiogenic, antibacterial and antipathogen applications. In synthetic organic chemistry, coumarin be the property of benzopyron group having cyclic lactone ring. In 1820, it was firstly detected by A.Vogel from tonka beans and sweet clover and termed as coumarin by Guibourt. In 1869, for the first time it was prepared in the research laboratory by Perkin. The most intimate naturally available origin for coumarin are Tonka bean (*Dipteryx odorata*), Vanilla grass (*Anthoxanthum odoratum*), Cassia (little coumarin), Sweet clover (*Melilotus*) etc. Shikimic acid pathway and Birch Donovan pathway are the major pathways for the preparation of coumarin.<sup>20</sup> The derivatives of coumarin happen extensively in umbelliferae, rutaceae, thymelaceae, and solanaceae etc.<sup>21-22</sup> Naturally and Synthetically available coumarins are the main source in therapeutic drug synthesis. These compounds contains pharmaceutical importance and grabbing anti – inflammatory,<sup>23-24</sup> anticoagulant<sup>25</sup>, anti- tuberculosis, anti- fungal, anti – bacterial belongings<sup>26-27</sup>. Considering recent years, the synthesis of coumarin contains various forms of its derivatives. Their medicinal properties are based on their method of substitution. Many scientists have prepared coumarin build novel medicinal factor by virtue of molecular hybridization procedure which provide and magnificent chance for evolution of different compounds with excellent biological activity by combining various pharmacophores. The literature studies admit that coumarin exhibit anti-proliferative activity against neoplasm.<sup>28</sup> Various screening trials organized on these compounds exhibit optimistic activity resistant to different types of cancer like metastatic renal cell carcinoma, malignant melanoma, prostate cancer etc.<sup>29-30</sup> For all these advantages related to


thiazoles and coumarin derivatives and following our work, we describe here the preparation of new library of thiazole derivatives from (E)-2-(1-(2-oxo-2H-chromen-3yl)ethylidene)hydrazinecarbothioamide




**Structure of Thiazole**




**Pramipexole (dopamine D<sub>2</sub>- agonist)**




**Riluzole ( neuroprotective)**



**Ethoxzolamide (diuretics)**



**Febuxostat (xanthine oxidase inhibitor)**




**Famotidine (H<sub>2</sub> receptor antagonist)**

## Structure of drugs containing thiazole nucleus

### RESULT AND DISCUSSION

Gradually, we begin our work with the treatment of substituted  $\alpha,\alpha$ -dibromoketones with (E)-2-(1-(2-oxo-2H-chromen-3yl)ethylidene)hydrazinecarbothioamide (**2a**) and the solvent used was ethanol while stirring at normal temperature. The reaction takes place according to assumption to synthesize the thiazole compound 3-(1-(2-(4-chloro phenyl) thiazol-2-yl) hydrazineylidene) ethyl)-2H-chromen-2-one (**3a**) with 80% yield. During the initial stage of reaction the reactants were completely soluble in solvent and after the completion of reaction a yellowish brown solid was obtained. Significantly, the reaction was executed with numerous substituted  $\alpha,\alpha$ -dibromoketones (**3b-3g**) to provide the comparable derivatives of thiazoles. The synthetic arrangement of (**3a**) was confirmed over evidence of spectral proof (NMR,IR) and elementary examination. The <sup>1</sup>H NMR range shows signals at  $\delta$  2.12 (s, 3H, CH<sub>3</sub>), 7.19 (s, thiazolyl-H), 7.35- 8.16 (m, 8H, Ar-H), 8.45 (s, coumarinyl-H). The <sup>13</sup>C NMR spectra display signals at  $\delta$  4.9, 105.4, 116.5, 118.6, 123.9, 125.8, 127.2, 128.3, 128.1, 128.8, 129.4, 129.7, 131.7, 133.9, 133.8 according to our assumption. By doing thin layer chromatography of the reaction mixture suggested the construction of solitary product. Regular workout of the reaction mixture subsequently purify the unrefined solid by recrystallization with ethanol and washing with water to obtain the pure form of thiazole derivatives. The same procedure is applied for the synthesis and purification of compounds **3b-3g**.





Where R = H, Cl, Br, NO<sub>2</sub>, CH<sub>3</sub>, F, OCH<sub>3</sub>

SCHEME 1 -  $\alpha$ ,  $\alpha$ -Dibromoketones reagent during preparation of various new thiazol-2-yl hydrazineylidene ethyl-2H-chromen-2-one.

TABLE 1 Physical data of thiazolylchromenones

COMPOUND	MOLECULAR FORMULA	MELTING POINT (°c)	YIELD %
3a	C <sub>20</sub> H <sub>14</sub> ClN <sub>3</sub> O <sub>2</sub> S	170-171	80
3b	C <sub>20</sub> H <sub>14</sub> BrN <sub>3</sub> O <sub>2</sub> S	174-175	92
3c	C <sub>21</sub> H <sub>17</sub> N <sub>3</sub> O <sub>3</sub> S	168-169	88
3d	C <sub>21</sub> H <sub>17</sub> N <sub>3</sub> O <sub>2</sub> S	178-180	93
3e	C <sub>20</sub> H <sub>14</sub> N <sub>4</sub> O <sub>4</sub> S	194-195	85
3f	C <sub>20</sub> H <sub>15</sub> N <sub>3</sub> O <sub>2</sub> S	185-186	78
3g	C <sub>20</sub> H <sub>14</sub> FN <sub>3</sub> O <sub>2</sub> S	204-205	88

## EXPERIMENTATION

The necessitate  $\alpha,\alpha$ -dibromoketones were incorporated on the report of publications procedure and characterized by comparing their melting point<sup>31</sup>. (Boeykens, M.; Kimpe, N. D. **Tetrahedron**, 1994). The required 3-acetyl coumarin for the present study was synthesized by stirring salicylaldehyde, ethylacetoacetate and piperidine for 5 min and enable to cool and yellow coloured solid was formed.<sup>32</sup> According to literature studies Mahadi Ali et al. and Vekariya H. synthesized (E)-2-(1-(2-oxo-2H-chromen-3-yl)ethylidene)hydrazinecarbothioamide (**2a**) on refluxing by adding glacial acetic acid and HCl as a stimulant but we synthesized it with modest moderation<sup>32</sup>. During its preparation, calculated amount of 3-acetyl coumarin (**1a**) and thiosemicarbazide (**1b**) was stirred and the solvent used was ethanol. After the achievement of reaction a yellow coloured solid product was drawn.<sup>33</sup>

All the solvents and the chemicals which were used during synthesis were of analytical research grade purchased from Spectrochem chemicals Ltd. (Mumbai, India). Time to time the accomplishment of the reaction was observed from analytical thin layer chromatography (TLC) by making use of Aluminium Merck TLC silica gel plates.

Melting point measured on open capillary tubes on an electrothermal apparatus and were left uncorrected. The instrument used for IR characterization was PerkinElmer spectrum IR version 10.6.2. All the NMR data were recorded on Bruker Avance NEO 500 MHz NMR spectrometer SAIF, P.U. and the solvent used was DMSO.

## CHARACTERIZATION

### **3-(1-(2-(4-chlorophenyl)thiazol-2-yl) ethylidene)ethyl)-2H-chromen-2-one** (**3a**)

Yellowish brown Powder, M.pt.170-171 °C.

IR ( $\nu_{\max}$ , KBr): 1719 (C=O), 3487 (N-H), 1672 (C=N).

<sup>1</sup>H NMR (DMSO-d<sub>6</sub> 500MHz):  $\delta$  2.12 (s, 3H, CH<sub>3</sub>), 7.19 (s, thiazolyl-H), 7.35-8.16 (m, 8H, Ar-H), 8.45 (s, coumarinyl-H).

<sup>13</sup>C NMR (DMSO-d<sub>6</sub> 500MHz):  $\delta$  4.9, 105.4, 116.5, 118.6, 123.9, 125.8, 127.2, 128.3, 128.1, 128.8, 129.4, 129.7, 131.7, 133.9, 133.8, 150.6, 153.4, 155.8, 159.6, 1713.

*Anal.* Calculated for C<sub>20</sub>H<sub>14</sub>ClN<sub>3</sub>O<sub>2</sub>S: C, 60.69; H, 3.58; S, 8.12; Found: C, 60.79; H, 3.78; S, 8.07;

Molecular wt.: 395.05. m/z: 395.12, 397.13, 397.11.

### **3-(1-(2-(4-Bromophenyl)thiazol-2-yl) hydrazineylidene)ethyl)-2H-chromen-2-one (3b)**

Dark brown powder ; M.pt.174-175 °C.

IR ( $\nu_{\max}$ , KBr): 1748 (C=O), 3457 (N-H), 1645 (C=N).

$^1\text{H}$  NMR (DMSO- $d_6$  500MHz):  $\delta$  2.12 (s, 3H, CH<sub>3</sub>), 7.34-7.78 (m, 8H, Ar-H), 7.39 (s, thiazolyl-H), 8.47(s, coumarinyl-H).

$^{13}\text{C}$  NMR (DMSO- $d_6$  500MHz):  $\delta$  4.9, 105.5, 116.6, 118.8, 123.3, 123.6, 125.5, 127.2, 128.4, 128.1, 128.3, 132.5, 132.7, 132.0, 133.3, 150.5, 153.7, 155.4, 159.3, 171.6.

*Anal.* Calculated For C<sub>20</sub>H<sub>14</sub>BrN<sub>3</sub>O<sub>2</sub>S: C, 54.59; H, 3.25; S, 7.20; Found: C, 54.75; H, 3.13; S, 7.02;

Molecular wt.: 440.32 m/z: 439.07, 441.09, 442.5

### **3-(1-(2-(4-methoxyphenyl)thiazol-2-yl) hydrazineylidene)ethyl)-2H-chromen-2-one (3c)**

Dark yellow Powder ; M.pt.168-169 °C

IR ( $\nu_{\max}$ , KBr): 1733 (C=O), 3475 (N-H), 1669 (C=N).

$^1\text{H}$  NMR (DMSO- $d_6$  500MHz):  $\delta$  2.12 (s, 3H, CH<sub>3</sub>), 3.73 (s, 3H, CH<sub>3</sub>), 7.18 (s, thiazolyl-H), 7.15-7.78 (m, 8H, Ar-H), 8.42 (s, coumarinyl-H).

$^{13}\text{C}$  NMR (DMSO- $d_6$  500MHz):  $\delta$  4.9, 55.6, 105.6, 114.8, 114.9, 116.9, 118.6, 123.7, 125.4, 125.8, 127.2, 128.3, 128.6, 128.3, 133.8, 150.2, 153.7, 155.3, 159.7, 160.5, 171.4.

*Anal:* Calculated For C<sub>21</sub>H<sub>17</sub>N<sub>3</sub>O<sub>3</sub>S: C, 64.47; H, 4.30; S, 8.18; Found C, 64.57; H, 4.26; S, 8.00;

Molecular wt.: 391.45 m/z: 391.24, 392.22, 393.15.

### **3-(1-(2-(4-p-tolyl) thiazol-2-yl) hydrazineylidene) ethyl)-2H-chromen-2-one (3d)**

Light brown Powder; M.pt. 178-180 °C.

IR ( $\nu_{\max}$ , KBr ): 1723 (C=O), 3476 (N-H), 1658 (C=N).

$^1\text{H}$  NMR (DMSO- $d_6$  500 MHz):  $\delta$  2.25 (s, 3H, CH<sub>3</sub>), 2.28 (s, 3H, CH<sub>3</sub>), 7.19 (s, thiazolyl-H), 7.36-7.78 (m, 8H, Ar-H), 8.19 (s, coumarinyl-H).

$^{13}\text{C}$  NMR (DMSO- $d_6$ , 500MHz):  $\delta$  4.4, 21.9, 105.6, 116.8, 118.9, 123.8, 125.9, 125.6, 125.8, 127.4, 128.6, 129.9, 129.9, 130.5, 131.0, 133.6, 150.8, 153.3, 155.7, 159.9, 171.7.

*Anal:* Calculated for C<sub>21</sub>H<sub>17</sub>N<sub>3</sub>O<sub>2</sub>S: C, 67.19; H, 4.58; S, 8.57; Found C, 66.93; H, 4.49; S, 8.47;

Molecular wt.: 375.45 m/z: 375.24, 376.26, 377.33.

**3-(1-(2-(4-nitrophenyl)thiazol-2-yl) hydrazineylidene)ethyl)-2H-chromen-2-one (3e)**

Bright yellow powder ; M.pt.194-195°C.

IR ( $\nu_{\max}$ , KBr): 1767 (C=O), 3446 (N-H), 1640 (C=N).

$^1\text{H}$  NMR (DMSO- $d_6$  500 MHz):  $\delta$  2.12 (s, 3H, CH<sub>3</sub>) , 7.24 (s, thiazolyl-H), 7.35-8.39 (m, 8H, Ar-H), 8.44 (s, coumarinyl-H).

$^{13}\text{C}$ NMR(DMSO- $d_6$  500 MHz):  $\delta$  10.5, 105.7, 116.5, 118.4, 123.7, 124.9, 124.4, 125.7, 126.3, 126.5, 127.8, 128.6, 133.4, 139.5, 147.9, 150.6, 153.7, 155.6, 159., 171.5.

Anal: Calculated For C<sub>20</sub>H<sub>14</sub>N<sub>4</sub>O<sub>4</sub>S: C, 59.15; H, 3.49; S, 7.85; Found: C, 59.34; H, 3.37; S, 7.69;

Molecular wt.: 406.42. m/z: 406.19, 407.19, 408.15

**3-(1-(2-(4-phenylthiazol-2-yl) hydrazineylidene)ethyl)-2H-chromen-2-one (3f)**

Mustard yellow powder; M.pt.185-186°C.

IR ( $\nu_{\max}$ , KBr): 1758 (C=O), 1652 (C=N), 3445 (N-H).

$^1\text{H}$  NMR (DMSO- $d_6$  500MHz):  $\delta$  2.13 (s, 3H, CH<sub>3</sub>) , 7.34-7.75 ( m , 8H, Ar-H ), 7.39 (s, thiazolyl-H), 7.57 (s, Aryl-H), 8.47 (s, coumarinyl-H).

$^{13}\text{C}$ NMR(DMSO- $d_6$  500MHz):  $\delta$  4.9, 105.5, 116.4, 118.7, 123.4, 125.8, 127.9, 127.5, 127.5, 128.7, 128.4, 129.3, 129.3, 133.8, 133.5, 150.5, 153.6, 155.3, 159.7, 171.4.

Anal: Calculated For C<sub>20</sub>H<sub>15</sub>N<sub>3</sub>O<sub>2</sub>S: C, 66.49; H, 4.16; S, 8.84; Found C, 66.69; H, 4.05; S, 8.67;

Molecule wt.: 361.42. m/z: 361.15, 362.17, 363.16

**3-(1-(2-(4-fluorophenyl)thiazol-2-yl) hydrazineylidene)ethyl)-2H-chromen-2-one (3g)**

Rust brown powder; M.pt.204-205°C.

IR ( $\nu_{\max}$ , KBr): 1728 (C=O), 3467 (N-H), 1663 (C=N)

$^1\text{H}$  NMR (DMSO- $d_6$  500MHz):  $\delta$  2.13 (s, 3H, CH<sub>3</sub>), 7.34-7.78 (m, 8H, Ar-H), 7.39 (s, thiazolyl-H), 8.43 (s, coumarinyl-H).

$^{13}\text{C}$  NMR (DMSO- $d_6$  500MHz):  $\delta$  4.9, 105.7, 116.5, 116.7, 116.8, 118.9, 123.8, 125.4, 127.4, 128.5, 128.6, 130.7, 130.5, 133.4, 150.6, 153.8, 155.9, 159.8, 162.7, 171.3.



Anal: Calculated For C<sub>20</sub>H<sub>14</sub>FN<sub>3</sub>O<sub>2</sub>S: C, 63.34; H, 3.75; S, 8.47; Found: C, 63.43; H, 3.65; S, 8.27;

Molecular wt.: 379.41 m/z: 379.16, 380.18, 381.19

## CONCLUSION

The reaction examined in this work specifically signify the prominence of thiazoles in medicinal chemistry. On the basis of coumarin derivatives various biologically active compounds have been acquired. So, our synthesized compounds would be immense rich in pharmacological activities and to investigate their biological activity will be our future prospective which further will be more useful in medicinal world.

## ACKNOWLEDGEMENT

Authors are indebted to the higher officials of Baba Mastnath University Rohtak, Haryana for providing us this platform and lab facilities and also overwhelmed to all the faculty members for their inspiration and support.

## REFERENCES

1. R. Prakash, N. Sharma, L. Arora, R. Aggarwal, J. K. Kapoor, R. Pundeer, O. Prakash, Indian J. Heterocycl. Chem. **2019**, 29, 99.
2. L. Arora, R. Prakash, R. Pundeer, Synth. Commun. **2019**, 49, 1486.
3. O. Prakash, N. Sharma, K. Pannu, Synth. Commun. **2007**, 37, 1995.
4. V. K. Ahluwalia, B. Mehta, R. Kumar, Synth. Commun. **1989**, 19, 619.
5. V. K. Ahluwalia, B. Mehta, M. Rawat, Synth. Commun. **1992**, 22, 2697
6. N. Sharma, R. Prakash, O. Prakash, Indian J. Heterocycl. Chem **2016**, 25, 297
7. R. Pundeer, V. Kiran, R. Prakash, Sushma, S. C. Bhatia, C. Sharma, K. R. Aneja, Med. Chem. Res. **2016**, 21, 4043
8. D. Hazarika, P. Phukan, Tetrahedron **2017**, 73, 1374.
9. K. Kim, J. Cho, S. C. Yoon, J. Chem. Soc. Perkin Trans. **1995**, 1, 253.
10. R. C. Larock, Comprehensive Organic Transformations, 2<sup>nd</sup> ed., VCH Publishers Inc, New York U S A **1999**, p. 717.
11. N. De Kimpe, R. Verhe, The Chemistry of  $\alpha$ -Haloketones;  $\alpha$ -Haloaldehydes and  $\alpha$ -Haloimines (Eds: S. Patai, Z. Rapport), John Wiley and Sons, Chichester, **1988**, 1
12. M. Boeykens, N. D. Kimpe, Tetrahedron **1994**, 50, 12349.
13. W. L. Evans, B. T. Brooks, J. Am. Chem. Soc. **1908**, 30, 406.

14. V. K. Ahluwalia, K. K. Arora, G. Kaur, B. Mehta, *Synth. Commun.* **1987**, 17, 333.
15. A. Kumar, R. Prakash, S. P. Singh, *Synth. Commun.* **2005**, 35, 461.
16. R. Prakash, A. Kumar, S. P. Singh, *Synth. Commun.* **2007**, 37, 2501.
17. R. Prakash, A. Kumar, S. P. Singh, R. Aggarwal, O. Prakash, *Indian J. Chem. Sect. A: Inorg. Bio-inorg. Phys. Theor. Anal. Chem.* **2007**, 46B, 1713.
18. R. Pundeer, V. Kiran, Sushma, O. Prakash, S. C. Bhatia, *Der Pharma Chemica* **2011**, 3, 109.
19. R. Pundeer, Sushma, C. Sharma, K. R. Aneja, *Int. J. Adv. Res. Pharm. Biol. Sci.* **2013**, 3, 102.
20. O. S. Taito. "Naturally occurring Coumarins and related physiological activities". *J. Pharm. Sci.* **1964**; 53: 231-264.
21. K. Lalitha, S. Nagarajan, "Strongly fluorescent organogels and self-assembled nanostructures from pyrene coupled coumarin derivatives: application in cell imaging". *J. Mater. Chem. B.*, **2015**; 3: 5690-5701.
22. L. Kun, X. Hao-Ran, Y. Kang-Kang, H. Ji-Ting, Y. Xiao-Qi, "A coumarin-based chromogenic and ratiometric probe for hydrazine". *Anal. Methods*, **2013**; 5: 2653-2656.
23. E. S. Darwish, A. M. A. Fattah, F. A. Attaby, O. N. Al Shayea. "Synthesis and Antimicrobial evaluation of some novel Thiazole, Pyridine, Pyrazole, Chromene,Hydrazone derivatives bearing biological active Sulfonamide moiety". *Int. J. Mol. Sci.*, **2014**; 15: 1237-1254
24. K. I. Shamil Nizamov, M. V. Willig, V. N. Sednev, Belov, S. W. Hell. "phosphorylated 3-heteroaryl coumarins and their use in fluorescence microscopy and nanoscopy". *Chem. Eur. J.*, **2012**; 18: 16339 – 16348.
25. M. A. Azagarsamy, D. D. Makinnon, D. L. Alge, K. S. Anseth, "Coumarin-Based Photodegradable Hydrogel: Design, Synthesis, Gelation, and Degradation Kinetics". *ACS Macro Lett.*, **2014**; 3: 515-519.
26. R. S. Keri, B. S. Sasidhar, B. M. Nagaraja, M. A. Santos, "Recent progress in the drug development of coumarin derivatives as potent antituberculosis agents". *Eur. J. Med. Chem.*, **2015**; 100: 257-269
27. R. Kharb, M. Kaur, A. K. Sharma, "Imperative Advances on Antimicrobial Activity of Coumarin Derivatives". *Int. J. Pharm. Sci. Rev. Res.*, **2013**; 20: 87-94.

28. N. Fu, S. Wang, Y. Zhang, C. Zhang, D. Yang, L. weng. "Efficient click chemistry towards fatty acids containing 1,2,3-triazole: Design and synthesis as potential antifungal drugs for *Candida albicans*". *Eur. J Med Chem.*, **2017**; 136: 596
29. Ali doregirae, K. Esmat tavakolinejad, K. Hojatollah, P. Behjat. "Synthesis of new 1,3-thiazole derivatives; using 1-(4-carbamoylphenyl)-3-methylthiourea and 1-methyl-3-(quinolin-8-yl)thiourea as starting materials". *J. Chil. Chem. Soc.*, **2015**; 60: 3021-3023.
30. E. A. Kesicki, M. A. Bailey, Y. Ovechkina et. al., "Synthesis and evaluation of the 2-aminothiazoles as anti-tubercular agents". *Plos One*, **2016**; 11(5).
31. Boeykens, M.; Kimpe, N. D. *Tetrahedron*, **1994**, 50, 12349.
32. Kotthireddy Kavitha, Devulapally Srikrishna, Pramod Kumar Dubey and Pasula Aparna A brief review of synthesis and applications of individual coumarin, thiazole scaffold as well as coumarin – thiazole hybrid compounds in the field of science abd technology. *IJMPR* **2018**, 2(5), 84-110
33. Ali Mahdi, Yasameen K. Al-Majedy Synthesis Of some coumarin-ethylideneamino-2-thioxoimidazolin-4-one derivatives. *WJPLS*, **2020**, 6 (2).

